PMID- 12048361
OWN - NLM
STAT- MEDLINE
DCOM- 20020712
LR  - 20200930
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 30
IP  - 1
DP  - 2002 May 1
TI  - Impact of suppression of viral replication by highly active antiretroviral 
      therapy on immune function and phenotype in chronic HIV-1 infection.
PG  - 33-40
AB  - We compared immune phenotypes, lymphocyte proliferation (LP), and delayed type 
      hypersensitivity (DTH) responses in 28 male antiretroviral treatment-naive and 
      experienced HIV-1-infected patients, matched pair-wise according to age and CD4+ 
      T-lymphocyte count. Median CD4+ T-lymphocyte counts were 441 cells/microL and 483 
      cells/microL and median CD4+ T-lymphocyte nadirs were 435 cells/microL and 150 
      cells/microL in both groups, respectively. Absolute numbers of circulating 
      T-lymphocyte subpopulations and proportions of naive and memory T-lymphocytes 
      were comparable in the two groups. Untreated patients had greater proportions of 
      activated CD4+ (p <.05) and CD8+ (p <.01) T-cells expressing human leukocyte 
      antigen (HLA)DR and CD38 and fewer CD8+ cells expressing CD28 (p <.05). DTH and 
      LP responses were comparable in both groups except for HIVp24, LP responses, and 
      mumps DTH responses, which were of greater magnitude in the group treated with 
      highly active antiretroviral therapy (HAART) (p <.05). Thus, HIV-1-infected 
      patients who experienced substantial increases in CD4+ T-lymphocyte counts after 
      suppression of viral replication on HAART had fewer activated lymphocytes and 
      similar immune function when compared with findings in untreated patients with 
      similar CD4+ T-cell counts. HIV replication has minimal real-time effect on CD4+ 
      T-cell function in response to non-HIV antigens but helper T-cell responses to 
      HIV-gag antigen are impaired during ongoing viral replication and may be restored 
      by antiretroviral therapy.
FAU - Lange, Christoph G
AU  - Lange CG
AD  - Department of Medicine, Division of Infectious Diseases, Center for AIDS 
      Research, Case Western Reserve University and University Hospitals of Cleveland, 
      Ohio 44106, USA.
FAU - Lederman, Michael M
AU  - Lederman MM
FAU - Madero, Juan Sierra
AU  - Madero JS
FAU - Medvik, Kathy
AU  - Medvik K
FAU - Asaad, Robert
AU  - Asaad R
FAU - Pacheko, Christina
AU  - Pacheko C
FAU - Carranza, Claudia
AU  - Carranza C
FAU - Valdez, Hernan
AU  - Valdez H
LA  - eng
GR  - AI-36219/AI/NIAID NIH HHS/United States
GR  - AI-38858/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (CD28 Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Membrane Glycoproteins)
RN  - EC 3.2.2.5 (ADP-ribosyl Cyclase)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.5 (NAD+ Nucleosidase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase
MH  - ADP-ribosyl Cyclase 1
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - *Antigens, CD
MH  - Antigens, Differentiation/analysis
MH  - *Antiretroviral Therapy, Highly Active
MH  - CD28 Antigens/analysis
MH  - CD4 Lymphocyte Count
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Chronic Disease
MH  - Cross-Sectional Studies
MH  - HIV Infections/*drug therapy/immunology/virology
MH  - *HIV-1
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Hypersensitivity, Delayed/etiology
MH  - Lymphocyte Activation/drug effects
MH  - Lymphocyte Count
MH  - Male
MH  - Membrane Glycoproteins
MH  - NAD+ Nucleosidase/analysis
MH  - T-Lymphocytes/*immunology
EDAT- 2002/06/06 10:00
MHDA- 2002/07/13 10:01
CRDT- 2002/06/06 10:00
PHST- 2002/06/06 10:00 [pubmed]
PHST- 2002/07/13 10:01 [medline]
PHST- 2002/06/06 10:00 [entrez]
AID - 10.1097/00042560-200205010-00005 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2002 May 1;30(1):33-40. doi: 
      10.1097/00042560-200205010-00005.